Oncocyte and Anbio Biotechnology: Comparing Two Manufacturing Giants

An in-depth look at the strengths and weaknesses of these two biotech companies.

Published on Feb. 17, 2026

Got story updates? Submit your updates here. ›

Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN) are both manufacturing companies operating in the biotech industry. This article compares the two businesses based on factors like revenue, earnings, profitability, institutional ownership, and analyst recommendations to determine which is the superior investment.

Why it matters

As publicly traded biotech companies, the performance and outlook of Oncocyte and Anbio Biotechnology are important for investors looking to gain exposure to the rapidly evolving diagnostics and medical technology sectors. Understanding the relative strengths and weaknesses of these two firms can help inform investment decisions.

The details

The analysis finds that Anbio Biotechnology has higher revenue and earnings than Oncocyte. Anbio also outperforms Oncocyte on 7 out of 9 key metrics compared. Anbio's strong institutional ownership suggests it is viewed favorably by major investors. Both companies operate in the in vitro diagnostics (IVD) space, with Anbio focused on a range of IVD products while Oncocyte specializes more in cancer detection tests.

  • The data in this article is current as of February 16, 2026.

The players

Oncocyte Corporation

A molecular diagnostics company that researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer.

Anbio Biotechnology

A company dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products, with a focus on transforming the diagnostics landscape through personalized and decentralized solutions.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the competitive dynamics in the biotech manufacturing space, with Anbio Biotechnology emerging as the stronger performer based on key financial and operational metrics. Investors looking to gain exposure to the IVD market may want to further research Anbio as a potential investment opportunity.